These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 30384885)

  • 1. Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial.
    Maron DJ; Mancini GBJ; Hartigan PM; Spertus JA; Sedlis SP; Kostuk WJ; Berman DS; Teo KK; Weintraub WS; Boden WE;
    J Am Coll Cardiol; 2018 Nov; 72(19):2297-2305. PubMed ID: 30384885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes.
    Mancini GBJ; Maron DJ; Hartigan PM; Spertus JA; Kostuk WJ; Berman DS; Teo KK; Weintraub WS; Boden WE;
    J Am Coll Cardiol; 2019 Apr; 73(16):2049-2058. PubMed ID: 31023428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factor control for coronary artery disease secondary prevention in large randomized trials.
    Farkouh ME; Boden WE; Bittner V; Muratov V; Hartigan P; Ogdie M; Bertolet M; Mathewkutty S; Teo K; Maron DJ; Sethi SS; Domanski M; Frye RL; Fuster V
    J Am Coll Cardiol; 2013 Apr; 61(15):1607-15. PubMed ID: 23500281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomised controlled trial.
    Ijzelenberg W; Hellemans IM; van Tulder MW; Heymans MW; Rauwerda JA; van Rossum AC; Seidell JC
    BMC Cardiovasc Disord; 2012 Sep; 12():71. PubMed ID: 22962863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
    Maron DJ; Boden WE; O'Rourke RA; Hartigan PM; Calfas KJ; Mancini GB; Spertus JA; Dada M; Kostuk WJ; Knudtson M; Harris CL; Sedlis SP; Zoble RG; Title LM; Gosselin G; Nawaz S; Gau GT; Blaustein AS; Bates ER; Shaw LJ; Berman DS; Chaitman BR; Weintraub WS; Teo KK;
    J Am Coll Cardiol; 2010 Mar; 55(13):1348-58. PubMed ID: 20338496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.
    Bittner V; Bertolet M; Barraza Felix R; Farkouh ME; Goldberg S; Ramanathan KB; Redmon JB; Sperling L; Rutter MK;
    J Am Coll Cardiol; 2015 Aug; 66(7):765-773. PubMed ID: 26271057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Controlled Trial of E-Counseling for Hypertension: REACH.
    Nolan RP; Feldman R; Dawes M; Kaczorowski J; Lynn H; Barr SI; MacPhail C; Thomas S; Goodman J; Eysenbach G; Liu S; Tanaka R; Surikova J
    Circ Cardiovasc Qual Outcomes; 2018 Jul; 11(7):e004420. PubMed ID: 30006474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global cardiovascular mortality risk in the adult Polish population: prospective assessment of the cohorts studied in multicentre national WOBASZ and WOBASZ Senior studies.
    Piotrowski W; Waśkiewicz A; Cicha-Mikołajczyk A
    Kardiol Pol; 2016; 74(3):262-73. PubMed ID: 26365939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prevention programme of ischaemic heart disease in the elderly: A randomised clinical trial.
    Marcos-Forniol E; Meco JF; Corbella E; Formiga F; Pintó X
    Eur J Prev Cardiol; 2018 Feb; 25(3):278-286. PubMed ID: 29164902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of healthy lifestyle on mortality in people with normal blood pressure, LDL cholesterol, and C-reactive protein.
    King DE; Mainous AG; Matheson EM; Everett CJ
    Eur J Prev Cardiol; 2013 Feb; 20(1):73-9. PubMed ID: 21965516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.
    Acharjee S; Teo KK; Jacobs AK; Hartigan PM; Barn K; Gosselin G; Tanguay JF; Maron DJ; Kostuk WJ; Chaitman BR; Mancini GB; Spertus JA; Dada MR; Bates ER; Booth DC; Weintraub WS; O'Rourke RA; Boden WE;
    Am Heart J; 2016 Mar; 173():108-17. PubMed ID: 26920603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry.
    Urbinati S; Olivari Z; Gonzini L; Savonitto S; Farina R; Del Pinto M; Valbusa A; Fantini G; Mazzoni A; Maggioni AP;
    Eur J Prev Cardiol; 2015 Dec; 22(12):1548-56. PubMed ID: 25452625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
    Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
    BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in geographic variation in the use of percutaneous coronary intervention for stable ischemic heart disease after publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
    Mohan AV; Fazel R; Huang PH; Shen YC; Howard D
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):125-30. PubMed ID: 24347661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease.
    van Zuilen AD; Bots ML; Dulger A; van der Tweel I; van Buren M; Ten Dam MA; Kaasjager KA; Ligtenberg G; Sijpkens YW; Sluiter HE; van de Ven PJ; Vervoort G; Vleming LJ; Blankestijn PJ; Wetzels JF
    Kidney Int; 2012 Sep; 82(6):710-7. PubMed ID: 22739979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cardiac rehabilitation in secondary prevention after coronary events.
    Peersen K; Munkhaugen J; Gullestad L; Liodden T; Moum T; Dammen T; Perk J; Otterstad JE
    Eur J Prev Cardiol; 2017 Sep; 24(13):1360-1368. PubMed ID: 28664773
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.